CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 134 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,706,165 | +55.5% | 181,500 | +14.2% | 0.00% | +100.0% |
| Q2 2023 | $1,739,955 | +9.2% | 158,900 | -13.0% | 0.00% | 0.0% |
| Q1 2023 | $1,593,144 | +221.8% | 182,700 | +67.6% | 0.00% | – |
| Q1 2021 | $495,000 | -20.9% | 109,000 | 0.0% | 0.00% | – |
| Q4 2020 | $626,000 | +257.7% | 109,000 | -7.9% | 0.00% | – |
| Q1 2020 | $175,000 | -24.6% | 118,400 | 0.0% | 0.00% | – |
| Q4 2019 | $232,000 | -60.9% | 118,400 | +2.2% | 0.00% | -100.0% |
| Q3 2019 | $593,000 | -26.6% | 115,900 | +2.7% | 0.00% | 0.0% |
| Q2 2019 | $808,000 | -45.0% | 112,900 | +2.1% | 0.00% | -50.0% |
| Q1 2019 | $1,469,000 | +88.1% | 110,600 | +11.5% | 0.00% | +100.0% |
| Q4 2018 | $781,000 | -27.1% | 99,200 | +2.6% | 0.00% | 0.0% |
| Q3 2018 | $1,071,000 | -17.5% | 96,700 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,298,000 | – | 96,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |